ContextLogic Inc. (LOGC)
(Delayed Data from NSDQ)
$6.07 USD
+0.07 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $6.06 -0.01 (-0.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.07 USD
+0.07 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $6.06 -0.01 (-0.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs
by Zacks Equity Research
Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs are part of the Zacks top Analyst Blog .
5 Big Winners as Dollar Strengthens on Fed Rate Hike
by Tirthankar Chakraborty
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.
5 Winning Stocks Backed by the Overlooked Trick of Rising P/E
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI).
LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
LogicBio Therapeutics (LOGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will LogicBio Therapeutics (LOGC) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
LogicBio Therapeutics (LOGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LogicBio Therapeutics (LOGC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
LogicBio Therapeutics (LOGC) delivered earnings and revenue surprises of -32.00% and -83.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Bet on 5 Top Stocks With Rising P/E for Spectacular Returns
by Sanghamitra Saha
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
LogicBio Therapeutics (LOGC) Jumps: Stock Rises 6.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LogicBio Therapeutics (LOGC) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.